R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group

A O Gang; C Strøm; M Pedersen; F d'Amore; L M Pedersen; Anne Bukh; B B Pedersen; M B Moeller; L S Mortensen; O V Gadeberg; S Ingeberg; T Mourits-Andersen; Stanislaw Pulczynski; P D Nully Brown

doi:10.1093/annonc/mdr058

R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group

A O Gang, C Strøm, M Pedersen, F d'Amore, L M Pedersen, Anne Bukh, B B Pedersen, M B Moeller, L S Mortensen, O V Gadeberg, S Ingeberg, T Mourits-Andersen, Stanislaw Pulczynski, P D Nully Brown

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstrakt

Optimal treatment of young patients with high-risk diffuse large B-cell lymphoma (DLBCL) remains a matter of debate and requires improvement. The combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) with addition of etoposide (CHOEP) has in other patient groups been shown to be effective. Further improvement has been accomplished with the use of rituximab in combination with the regimens every 2 weeks (R-CHOP-14, R-CHOEP-14). The aim of the present retrospective population-based study was to compare R-CHOP-14 with R-CHOEP-14 in a cohort of high-risk patients aged 18-60 years with two or more risk factors (stage III-IV, elevated lactate dehydrogenase levels, performance status 2-4). To our knowledge, this is the first study comparing these two regimens in this patient group.

Originalsprog	Engelsk
Tidsskrift	Annals of Oncology
Vol/bind	23
Udgave nummer	1
Sider (fra-til)	147-53
Antal sider	7
ISSN	0923-7534
DOI	https://doi.org/10.1093/annonc/mdr058
Status	Udgivet - 2012

Dokumenter og links

10.1093/annonc/mdr058

Citationsformater

Gang, A. O., Strøm, C., Pedersen, M., d'Amore, F., Pedersen, L. M., Bukh, A., Pedersen, B. B., Moeller, M. B., Mortensen, L. S., Gadeberg, O. V., Ingeberg, S., Mourits-Andersen, T., Pulczynski, S., & Brown, P. D. N. (2012). R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Annals of Oncology, 23(1), 147-53. https://doi.org/10.1093/annonc/mdr058

Gang, A O ; Strøm, C ; Pedersen, M ; d'Amore, F ; Pedersen, L M ; Bukh, Anne ; Pedersen, B B ; Moeller, M B ; Mortensen, L S ; Gadeberg, O V ; Ingeberg, S ; Mourits-Andersen, T ; Pulczynski, Stanislaw ; Brown, P D Nully. / R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. I: Annals of Oncology. 2012 ; Bind 23, Nr. 1. s. 147-53.

@article{a2430133e61345a2bb9854b15f9cfb9e,

title = "R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group",

abstract = "Optimal treatment of young patients with high-risk diffuse large B-cell lymphoma (DLBCL) remains a matter of debate and requires improvement. The combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) with addition of etoposide (CHOEP) has in other patient groups been shown to be effective. Further improvement has been accomplished with the use of rituximab in combination with the regimens every 2 weeks (R-CHOP-14, R-CHOEP-14). The aim of the present retrospective population-based study was to compare R-CHOP-14 with R-CHOEP-14 in a cohort of high-risk patients aged 18-60 years with two or more risk factors (stage III-IV, elevated lactate dehydrogenase levels, performance status 2-4). To our knowledge, this is the first study comparing these two regimens in this patient group.",

author = "Gang, {A O} and C Str{\o}m and M Pedersen and F d'Amore and Pedersen, {L M} and Anne Bukh and Pedersen, {B B} and Moeller, {M B} and Mortensen, {L S} and Gadeberg, {O V} and S Ingeberg and T Mourits-Andersen and Stanislaw Pulczynski and Brown, {P D Nully}",

year = "2012",

doi = "10.1093/annonc/mdr058",

language = "English",

volume = "23",

pages = "147--53",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Heinemann",

number = "1",

}

Gang, AO, Strøm, C, Pedersen, M, d'Amore, F, Pedersen, LM, Bukh, A, Pedersen, BB, Moeller, MB, Mortensen, LS, Gadeberg, OV, Ingeberg, S, Mourits-Andersen, T, Pulczynski, S & Brown, PDN 2012, 'R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group', Annals of Oncology, bind 23, nr. 1, s. 147-53. https://doi.org/10.1093/annonc/mdr058

R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. / Gang, A O; Strøm, C; Pedersen, M; d'Amore, F; Pedersen, L M; Bukh, Anne; Pedersen, B B; Moeller, M B; Mortensen, L S; Gadeberg, O V; Ingeberg, S; Mourits-Andersen, T; Pulczynski, Stanislaw; Brown, P D Nully.

I: Annals of Oncology, Bind 23, Nr. 1, 2012, s. 147-53.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

TY - JOUR

T1 - R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group

AU - Gang, A O

AU - Strøm, C

AU - Pedersen, M

AU - d'Amore, F

AU - Pedersen, L M

AU - Bukh, Anne

AU - Pedersen, B B

AU - Moeller, M B

AU - Mortensen, L S

AU - Gadeberg, O V

AU - Ingeberg, S

AU - Mourits-Andersen, T

AU - Pulczynski, Stanislaw

AU - Brown, P D Nully

PY - 2012

Y1 - 2012

N2 - Optimal treatment of young patients with high-risk diffuse large B-cell lymphoma (DLBCL) remains a matter of debate and requires improvement. The combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) with addition of etoposide (CHOEP) has in other patient groups been shown to be effective. Further improvement has been accomplished with the use of rituximab in combination with the regimens every 2 weeks (R-CHOP-14, R-CHOEP-14). The aim of the present retrospective population-based study was to compare R-CHOP-14 with R-CHOEP-14 in a cohort of high-risk patients aged 18-60 years with two or more risk factors (stage III-IV, elevated lactate dehydrogenase levels, performance status 2-4). To our knowledge, this is the first study comparing these two regimens in this patient group.

AB - Optimal treatment of young patients with high-risk diffuse large B-cell lymphoma (DLBCL) remains a matter of debate and requires improvement. The combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) with addition of etoposide (CHOEP) has in other patient groups been shown to be effective. Further improvement has been accomplished with the use of rituximab in combination with the regimens every 2 weeks (R-CHOP-14, R-CHOEP-14). The aim of the present retrospective population-based study was to compare R-CHOP-14 with R-CHOEP-14 in a cohort of high-risk patients aged 18-60 years with two or more risk factors (stage III-IV, elevated lactate dehydrogenase levels, performance status 2-4). To our knowledge, this is the first study comparing these two regimens in this patient group.

U2 - 10.1093/annonc/mdr058

DO - 10.1093/annonc/mdr058

M3 - Journal article

C2 - 21460380

VL - 23

SP - 147

EP - 153

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -

R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group

Abstrakt

Dokumenter og links

Fingeraftryk

Citationsformater